
Freda H Passam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9376078/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nature Communications, 2019, 10, 1322.	12.8	277
2	Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. Journal of Clinical Investigation, 2012, 122, 2104-2113.	8.2	257
3	Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood, 2007, 109, 422-430.	1.4	208
4	Pleural Effusions in Hematologic Malignancies. Chest, 2004, 125, 1546-1555.	0.8	194
5	How we diagnose the antiphospholipid syndrome. Blood, 2009, 113, 985-994.	1.4	167
6	Monocyte tissue factor–dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. Journal of Clinical Investigation, 2012, 122, 558-568.	8.2	150
7	Levels of Serum Cytokines and Acute Phase Proteins in Patients With Essential and Cancer-Related Thrombocytosis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 135-140.	1.3	142
8	Levels of Serum Cytokines and Acute Phase Proteins in Patients With Essential and Cancer-Related Thrombocytosis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 135-140.	1.3	126
9	Naturally occurring free thiols within β2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress–induced cell injury. Blood, 2010, 116, 1961-1970.	1.4	105
10	Quercetin-3-rutinoside Inhibits Protein Disulfide Isomerase by Binding to Its b′x Domain. Journal of Biological Chemistry, 2015, 290, 23543-23552.	3.4	90
11	Autoregulation of von Willebrand factor function by a disulfide bond switch. Science Advances, 2018, 4, eaaq1477.	10.3	79
12	Activated peripheral blood and endothelial cells in thalassemia patients. Annals of Hematology, 2001, 80, 577-583.	1.8	71
13	Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood, 2010, 116, 1995-1997.	1.4	60
14	Both platelet- and endothelial cell–derived ERp5 support thrombus formation in a laser-induced mouse model of thrombosis. Blood, 2015, 125, 2276-2285.	1.4	59
15	Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Annals of Hematology, 2003, 82, 19-23.	1.8	57
16	Ki-67 Proliferation Index. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 8-13.	1.3	57
17	Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative postâ€ŧranslational modification of beta 2 glycoprotein I. Journal of Thrombosis and Haemostasis, 2011, 9, 275-282.	3.8	56
18	Redox control of β2â€glycoproteinÂl–von Willebrand factor interaction by thioredoxinâ€1. Journal of Thrombosis and Haemostasis. 2010. 8. 1754-1762.	3.8	52

Freda H Passam

#	Article	IF	CITATIONS
19	Quantification of NETsâ€associated markers by flow cytometry and serum assays in patients with thrombosis and sepsis. International Journal of Laboratory Hematology, 2018, 40, 392-399.	1.3	52
20	Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity. American Journal of Hematology, 2003, 72, 229-233.	4.1	49
21	Mechano-redox control of integrin de-adhesion. ELife, 2018, 7, .	6.0	47
22	β2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. Journal of Thrombosis and Haemostasis, 2008, 6, 1215-1223.	3.8	44
23	Intestinal ischemia as the first manifestation of vasculitis. Seminars in Arthritis and Rheumatism, 2004, 34, 431-441.	3.4	43
24	Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate. Annals of Hematology, 2001, 80, 349-353.	1.8	38
25	Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clinica Chimica Acta, 2002, 325, 51-57.	1.1	38
26	Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. Journal of Hepatology, 2005, 42, 393-399.	3.7	38
27	Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. American Journal of Hematology, 2004, 75, 101-106.	4.1	37
28	Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leukemia Research, 2005, 29, 41-46.	0.8	36
29	Histological expression of angiogenic factors: VEGF, PDGFRα, and HIF-1α in Hodgkin lymphoma. Pathology Research and Practice, 2009, 205, 11-20.	2.3	36
30	Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. European Journal of Gastroenterology and Hepatology, 2002, 14, 1383-1387.	1.6	33
31	Laboratory tests for the antiphospholipid syndrome: current concepts. Pathology, 2004, 36, 129-138.	0.6	30
32	Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. Journal of Autoimmunity, 2005, 25, 283-288.	6.5	29
33	Protein disulfide isomerase regulation by nitric oxide maintains vascular quiescence and controls thrombus formation. Journal of Thrombosis and Haemostasis, 2018, 16, 2322-2335.	3.8	29
34	Thymoma with immunodeficiency (Good's syndrome): Review of the literature apropos three cases. Scandinavian Journal of Infectious Diseases, 2006, 38, 314-320.	1.5	28
35	Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. Journal of Hepatology, 2003, 39, 679-685.	3.7	27
36	In vivo modulation of angiogenesis by beta 2 glycoprotein I. Journal of Autoimmunity, 2010, 35, 232-240.	6.5	23

Freda H Passam

#	Article	IF	CITATIONS
37	Protein Disulfide Isomerase in Thrombosis. Seminars in Thrombosis and Hemostasis, 2015, 41, 765-773.	2.7	20
38	Angiogenic Molecules in Hodgkin's Disease: Results from Sequential Serum Analysis. International Journal of Immunopathology and Pharmacology, 2006, 19, 205873920601900.	2.1	19
39	Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. Journal of Molecular Histology, 2004, 35, 857-863.	2.2	14
40	Clinical significance of circulating endothelial adhesion molecules (sE-selectin and sICAM) in untreated multiple myeloma patients. Clinica Chimica Acta, 2004, 349, 39-43.	1.1	11
41	Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. International Journal of Laboratory Hematology, 2007, 30, 070129105256005-???.	0.2	10
42	l'eta 2-glycoprotein I protects mice against gram-negative septicaemia in a sexually dimorphic manner. Scientific Reports, 2017, 7, 8201.	3.3	9
43	Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: a methodological approach. Annals of Hematology, 2006, 85, 795-805.	1.8	8
44	An alternate covalent form of platelet αllbβ3 integrin that resides in focal adhesions and has altered function. Blood, 2021, 138, 1359-1372.	1.4	8
45	Thromboinflammation Model-on-A-Chip by Whole Blood Microfluidics on Fixed Human Endothelium. Diagnostics, 2021, 11, 203.	2.6	8
46	Straight Channel Microfluidic Chips for the Study of Platelet Adhesion under Flow. Bio-protocol, 2019, 9, e3195.	0.4	7
47	Functional Assays of Thiol Isomerase ERp5. Methods in Molecular Biology, 2019, 1967, 149-163.	0.9	3
48	Neutrophil Activation and Netosis Are the Key Drivers of Thrombosis in Heparin-Induced Thrombocytopenia. Blood, 2018, 132, 378-378.	1.4	3
49	Î'eta-2-glycoprotein I exerts antithrombotic function through its domain V in mice. Journal of Autoimmunity, 2022, 126, 102747.	6.5	3
50	Protein Disulfide Isomerase Inhibitors: A New Class of Antithrombotic Agents. Blood, 2011, 118, 369-369.	1.4	2
51	Role of Thiol Isomerase ERp5 in Thrombus Formation. Blood, 2011, 118, 370-370.	1.4	1
52	Mechano-Redox Control of Integrins in Thromboinflammation. Antioxidants and Redox Signaling, 2022, 37, 1072-1093.	5.4	1
53	The interaction of Beta 2 Glycoprotein I with vWF is thiol dependent and promotes the binding of GPIbα to vWF: Implications to the redox regulation of platelet adhesion. Clinical Biochemistry, 2011, 44, S255.	1.9	0
54	Investigation of redox modifications of platelet integrin GPIIb-IIIa in diabetes. Free Radical Biology and Medicine, 2018, 128, S55.	2.9	0

#	Article	IF	CITATIONS
55	Protein Disulphide Isomerase 6 (PDIA6) Attenuates Platelet Endoplasmic Reticulum Stress and Secretion in a Mouse Model. Blood, 2021, 138, 3138-3138.	1.4	0